Where is Ovoca Bio located?

Ovoca Bio is headquartered in Dublin, Ireland.

How many employees does Ovoca Bio have?

As of May 31, 2026, the latest employee count at Ovoca Bio is 2.

Is Ovoca Bio a funded company?

Ovoca Bio is a funded company, having raised a total of $***** in its 1st and only funding round.

Where does Ovoca Bio rank among its competitors?

Ovoca Bio ranks 2nd amongst 15 active competitors, of which 4 are funded. It stands 7th in terms of total funding among its competitors. The most recent competitor to raise funding was Estrigenix, which secured $2M in Jul, 2026.

Who are the top competitors of Ovoca Bio?

Ovoca Bio's top competitors include Abcellera Biologics, KaNDy Therapeutics and Tarsa Therapeutics. Among them, Estrigenix secured the most recent funding round in July, 2026.

Ovoca Bio - 2026 Company Profile, Team & Competitors

Ovoca Bio is a public company based in Dublin (Ireland), founded in 2018. It operates as a Developer of novel medicinal treatments for women's health conditions. This company focuses on the research, development, and commercialization of innovative therapies addressing significant unmet medical needs. A key product is a novel treatment for hypoactive sexual desire disorder (HSDD) in premenopausal women. The company actively seeks partnerships to accelerate the availability of its product candidates to patients. It holds a patent portfolio protecting its technology and lead product. The company's vision is to become a leader in women's health therapeutics.. The company has 15 active competitors, including 4 funded and 3 that have exited. Its top competitors include companies like Abcellera Biologics, KaNDy Therapeutics and Tarsa Therapeutics.

Company Details

{}

Website: ovocabio.com
Email ID: *****@ovocabio.com
Phone Number: +353 **********

Key Metrics

Founded Year

2018

Location

Dublin, Ireland

Stage

Public

Ranked

2^nd among 15 active competitors

Employee Count

2 as on May 31, 2026

Similar Companies

Abcellera Biologics & 17 more

Exit Details

Public

View Ovoca Bio's full profile

Ovoca Bio got listed on Jun 30, 2005.

Click here to take a look at Ovoca Bio's IPO in detail

Ovoca Bio has not raised any funding rounds yet.

Ovoca Bio's employee count trend

Ovoca Bio has 2 employees as of May 26. Here is Ovoca Bio's employee count trend over the years:

Uncover Ovoca Bio's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Ovoca Bio include Abcellera Biologics, KaNDy Therapeutics and Tarsa Therapeutics. Here is the list of Top 10 competitors of Ovoca Bio, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Abcellera Biologics 2012, Vancouver (Canada), Public	AI-enabled platform for antibodies discovery	$115M	DCVC, Orbimed & 16 others	71/100
2nd	Ovoca Bio 2018, Dublin (Ireland), Public	Developer of novel medicinal treatments for women's health conditions. This company focuses on the research, development, and commercialization of innovative therapies addressing significant unmet medical needs. A key product is a novel treatment for hypoactive sexual desire disorder (HSDD) in premenopausal women. The company actively seeks partnerships to accelerate the availability of its product candidates to patients. It holds a patent portfolio protecting its technology and lead product. The company's vision is to become a leader in women's health therapeutics.	-	-	42/100
3rd	KaNDy Therapeutics 2017, Stevenage (United Kingdom), Acquired	Developer of neurokinin antagonists for chronic debilitating female sex-hormone related conditions	$32.2M	Longitude Capital, Advent Life Sciences & 3 others	41/100
4th	Tarsa Therapeutics 2009, Philadelphia (United States), Series B	Developer of oral treatment for postmenopausal osteoporosis	$76.7M	Foresite Capital, Novo Holdings & 5 others	41/100
5th	Estrigenix 2018, Milwaukee (United States), Seed	Developer of estrogen-based therapeutics women health	$2M	Talents VC Fund, HHS	38/100
6th	Sojournix 2016, Waltham (United States), Deadpooled	Developer of drugs for hot flashes due to menopause	$78.4M	Boxer Capital, Venrock & 3 others	34/100
7th	Viramal 2013, London (United Kingdom), Series A	UK-based specialty biopharma developing novel drug delivery systems for hormone therapies	-	NCL Technology Ventures, NCL	32/100
8th	Vertical Pharmaceuticals 2003, Bridgewater (United States), Unfunded	Developer of drugs for reducing hot flashes due to menopause	-	-	30/100
9th	MenoGeniX 2010, Aurora (United States), Seed	Developing biopharmaceutical alternative therapies for menopausal vasomotor symptoms	$1.18M	HHS	27/100
10th	atmenopause.com 2019, United States, Unfunded	Developer of herbal treatment for menopausal symptoms	-	-	24/100